Text + image

<h2 style="white-space:pre-line">Pulmonary Arterial Hypertension Research</h2>
<p>Medilife researches innovative therapies for pulmonary arterial hypertension (PAH), a life-threatening lung condition. Our focus is on understanding PAH mechanisms and developing novel treatment strategies. This includes targeted drug delivery and combination therapies to improve efficacy and reduce side effects. Medilife is committed to improving PAH patient lives through better treatment and management. Our team collaborates to accelerate the development of effective PAH treatments.</p>

Medilife Innovations

Medilife Innovations Group Corp. is a forward-thinking startup driving innovation in bio-health.

We use Samsung ultrasound devices to provide services to nearly 1,000 pregnant women annually. These devices contribute to the diagnosis and prevention of various fetal diseases.

We provide cord blood and cord tissue storage services that offer access to mesenchymal stem cells, endothelial progenitor cells, epithelial progenitor cells, and more. These cells are being researched for their potential applications in regulating the immune system and treating vascular damage.

We are developing a new app that will:
Safely guide women through pregnancy and post-pregnancy stages.
Serve as a trustworthy resource hub and support tool.
Improve health outcomes for women and their families.

We provide ultrasound services to nearly 1,000 pregnant women annually. Leveraging AI, we aim to develop a new system that processes this extensive data to enhance diagnostic accuracy and improve disease prevention, ensuring better patient outcomes.